Research programme: antibacterial therapeutics - Dr Reddy's

Drug Profile

Research programme: antibacterial therapeutics - Dr Reddy's

Alternative Names: DRF 11057; DRF 12035; DRF 13792; DRF 16048; DRF 6163; DRF 8114; DRF 8129; DRF 8345; DRF 8417; DRL 11286; DRL 11291; DRL-19440; Oxazolidinone antibacterials research programme - Dr Reddy's

Latest Information Update: 27 Jul 2010

Price : $50

At a glance

  • Originator Dr Reddys Laboratories
  • Class Oxazolidinones
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 31 Mar 2010 Preclinical development is ongoing
  • 08 Feb 2008 Preclinical development is ongoing
  • 10 Sep 2003 DRF 11057 is available for licensing (http://www.drreddys.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top